MediciNova, Inc. (MNOV) |
|
2.46 -0.01 (-0.4%)
|
01-27 16:00 |
|
Open: |
2.44 |
Pre. Close: |
2.47 |
|
High:
|
2.49 |
Low:
|
2.41 |
|
Volume:
|
32,551 |
Market Cap:
|
121(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:46:20 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 3.01 One year: 3.51 |
| Support: |
Support1: 2.19 Support2: 1.95 |
| Resistance: |
Resistance1: 2.57 Resistance2: 3.01 |
| Pivot: |
2.43  |
| Moving Average: |
MA(5): 2.46 MA(20): 2.36
MA(100): 2.23 MA(250): 2.38 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 68.9 %D(3): 73.7 |
| RSI: |
RSI(14): 56.4 |
| 52-week: |
High: 3.18 Low: 1.95 |
| Average Vol(K): |
3-Month: 87 (K) 10-Days: 24 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MNOV ] has closed below upper band by 40.8%. Bollinger Bands are 42.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.49 - 2.51 |
2.51 - 2.52 |
|
Low:
|
2.38 - 2.39 |
2.39 - 2.41 |
|
Close:
|
2.43 - 2.46 |
2.46 - 2.48 |
|
Company Description |
|
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California. |
Headline News |
Thu, 12 Jan 2023
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma - Yahoo Finance
Wed, 11 Jan 2023
MediciNova to get Canadian patent linked to potential skin disorder ... - Seeking Alpha
Tue, 10 Jan 2023
Should You Buy Medicinova Inc (MNOV) Stock Tuesday Morning? - InvestorsObserver
Thu, 05 Jan 2023
MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast) - Yahoo Finance
Tue, 06 Dec 2022
MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation - Yahoo Finance
Tue, 29 Nov 2022
13 Best Biotech Penny Stocks To Buy Now - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
49 (M) |
| Shares Float |
42 (M) |
|
% Held by Insiders
|
2.9 (%) |
|
% Held by Institutions
|
25.2 (%) |
|
Shares Short
|
529 (K) |
|
Shares Short P.Month
|
669 (K) |
Stock Financials |
|
EPS
|
-0.28 |
|
EPS Est Next Qtl
|
1.86 |
|
EPS Est This Year
|
-0.35 |
|
EPS Est Next Year
|
-0.35 |
|
Book Value (p.s.)
|
1.49 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-10 |
|
Return on Equity (ttm)
|
-16.5 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0.08 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.28 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-13 (M) |
|
Levered Free Cash Flow
|
-8 (M) |
Stock Valuations |
|
PE Ratio
|
-9.05 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.65 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-9.63 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
